Exelixis Inc (EXEL)

21.28
0.09 0.42
NASDAQ : Health Care
Prev Close 21.37
Open 21.43
Day Low/High 21.20 / 21.92
52 Wk Low/High 3.55 / 8.74
Volume 2.90M
Avg Volume 5.27M
Exchange NASDAQ
Shares Outstanding 290.87M
Market Cap 6.08B
EPS -0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis Announces Webcasts Of Investor Conference Presentations In March

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 11,000 shares of Exelixis common stock and stock options to purchase an aggregate of 22,000...

Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update

Exelixis Announces Fourth Quarter And Full Year 2016 Financial Results And Provides Corporate Update

Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the fourth quarter and full year of 2016 and provided an update on progress toward delivering upon its key corporate objectives, as well as commercial and...

Exelixis Announces Clinical Trial Collaboration With Roche To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors

Exelixis Announces Clinical Trial Collaboration With Roche To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced a new collaboration with Roche on a phase 1b dose escalation study that will evaluate the safety and tolerability of cabozantinib, Exelixis' tyrosine kinase inhibitor (TKI), in...

Exelixis And Bristol-Myers Squibb Enter Clinical Collaboration For Late-Stage Combination Trial In First-Line Renal Cell Carcinoma

Exelixis And Bristol-Myers Squibb Enter Clinical Collaboration For Late-Stage Combination Trial In First-Line Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical development collaboration to evaluate CABOMETYXâ„¢ (cabozantinib), Exelixis' small...

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Incyte, Skyworks Solutions, Western Digital, Constellation Brands: 'Mad Money' Lightning Round

Jim Cramer is bullish on Incyte, Skyworks Solutions, Western Digital, Constellation Brands and more.

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

What You Should Do if This Market Is Overvalued: Cramer's 'Mad Money' Recap (Wednesday 2/22/17)

This market may be cheaper than it looks, especially if companies can keep delivering on the earnings front, says Jim Cramer.

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors

Exelixis Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors

Exelixis, Inc. (NASDAQ:EXEL) today announced results from a phase 1 trial of cabozantinib in combination with either nivolumab or nivolumab plus ipilimumab in patients with refractory genitourinary tumors.

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Morgan Stanley, Twitter, Tesaro: Doug Kass' Views

Doug Kass shares his thoughts on boosts to financials, and discusses what M&A speculation is doing to biotechs.

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15

Exelixis To Present At The Leerink Partners Global Healthcare Conference On February 15

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.

Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)

Banks, Oil, Deregulation and Your Investments: Cramer's 'Mad Money' Recap (Monday 2/6/17)

Jim Cramer isn't worried about a correction: He says this recent rally isn't just about Trump's agenda. It's about profits and earnings.

Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round

Box, Nucor, Exelixis, American Airlines and more: 'Mad Money' Lightning Round

Jim Cramer is bullish on Box, Nucor, and American Airlines; but bearish on AK Steel Holdings and Rite Aid.

Hopes for Tax Reform, Less Regulation Lift Indices

Hopes for Tax Reform, Less Regulation Lift Indices

Technical indicators indicate the markets are not extended and have consolidated nicely.

Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017

Exelixis To Release Fourth Quarter And Full Year 2016 Financial Results On Monday, February 27, 2017

Exelixis, Inc. (NASDAQ:EXEL) announced today that its fourth quarter and full year 2016 financial results will be released on Monday, February 27, 2017 after the markets close.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (Nasdaq:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 61,750 shares of Exelixis common stock and stock options to purchase an aggregate of 123,500...

Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan

Exelixis And Takeda Enter Into Exclusive Licensing Agreement To Commercialize And Develop Novel Cancer Therapy Cabozantinib In Japan

Exelixis, Inc. (NASDAQ:EXEL) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib,...

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

The Next Target in Biotech Land

The Next Target in Biotech Land

The Actelion buyout opens the way for other deals.

Home Depot, Marathon Petroleum, Huntsman: 'Mad Money' Lightning Round

Home Depot, Marathon Petroleum, Huntsman: 'Mad Money' Lightning Round

Jim Cramer likes Home Depot and prefers Schlumberger to SeaDrill Limited.

Investors Need a Strong Stomach as Trump Tweets: Cramer's 'Mad Money' Recap (Tuesday 1/17/17)

Investors Need a Strong Stomach as Trump Tweets: Cramer's 'Mad Money' Recap (Tuesday 1/17/17)

Crosscurrents are disruptive, and today's selloff demonstrates why investors need conviction -- and a strong stomach, says Jim Cramer.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Update On Dispute Between Exelixis And Genentech, A Member Of The Roche Group

Update On Dispute Between Exelixis And Genentech, A Member Of The Roche Group

Exelixis, Inc. (Nasdaq:EXEL) announced today that Genentech, Inc.

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Exelixis, Inc. (NASDAQ:EXEL) announced that today it granted restricted stock unit awards (RSUs) representing an aggregate of 17,750 shares of Exelixis common stock, and stock options to purchase an aggregate of 35,500...

Exelixis And Ipsen Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada

Exelixis And Ipsen Amend Exclusive Licensing Agreement For The Commercialization And Development Of Cabozantinib To Include Canada

Exelixis, Inc. (NASDAQ:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY) today jointly announced an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development of...

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

Exelixis Announces Leadership Hires In Public Affairs And Business Development To Support Growth Of Company And Pipeline

Exelixis Announces Leadership Hires In Public Affairs And Business Development To Support Growth Of Company And Pipeline

Exelixis, Inc. (NASDAQ:EXEL) today announced two high-level appointments designed to further strengthen the company's public affairs and business development capabilities following the launch of its newest medicine,...

Look at Silver Miners and Some Names That Have Pulled Back

Look at Silver Miners and Some Names That Have Pulled Back

I'm feeling pressure to force some trades today, but I'm trying to stay selective.

Exelixis To Present At The BMO Prescription For Success Healthcare Conference On December 14

Exelixis To Present At The BMO Prescription For Success Healthcare Conference On December 14

Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M.